Agreement enabled by Veracyte acquisition of NanoString diagnostics assets for global expansion
Veracyte (NASDAQ:VCYT) today announced a multi-year partnership with Acerta Pharma, the hematology research and development arm of AstraZeneca (NYSE:AZN), to provide genomic information that will support the biopharmaceutical company's development of oncology therapeutics. Financial and other terms of the collaboration were not disclosed.
The agreement marks Veracyte's first biopharmaceutical partnership since the company announced its acquisition of the exclusive diagnostics rights to the NanoString nCounter® platform and genomic tests in breast cancer and lymphoma on December 3, 2019. That transaction positions Veracyte to expand globally using a distributed platform and comprehensive menu of advanced genomic tests.